AbbVie (NYSE:ABBV) Price Target Raised to $270.00 at Morgan Stanley

AbbVie (NYSE:ABBV) had its price target increased by Morgan Stanley from $269.00 to $270.00 in a report issued on Thursday,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other research analysts have also commented on ABBV. BMO Capital Markets reissued an “outperform” rating and set a $258.00 price objective on shares of AbbVie in a report on Thursday, January 15th. JPMorgan Chase & Co. boosted their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Citigroup decreased their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a report on Monday, November 3rd. Finally, Berenberg Bank set a $275.00 target price on AbbVie in a research note on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $251.00.

AbbVie Price Performance

NYSE:ABBV opened at $218.44 on Thursday. AbbVie has a 1 year low of $164.39 and a 1 year high of $244.81. The stock’s fifty day moving average price is $223.81 and its two-hundred day moving average price is $219.14. The company has a market cap of $386.06 billion, a P/E ratio of 92.56, a P/E/G ratio of 0.89 and a beta of 0.35.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period in the previous year, the company posted $2.16 EPS. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts expect that AbbVie will post 12.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in AbbVie by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after purchasing an additional 3,032,438 shares during the period. Geode Capital Management LLC boosted its stake in shares of AbbVie by 2.4% during the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock valued at $7,240,169,000 after purchasing an additional 924,761 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of AbbVie by 6.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after purchasing an additional 1,517,222 shares during the last quarter. Norges Bank purchased a new position in shares of AbbVie in the second quarter worth $4,288,200,000. Finally, Legal & General Group Plc raised its holdings in AbbVie by 4.3% during the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after buying an additional 493,420 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and 2026 outlook raised — AbbVie reported Q4 revenue and adjusted EPS above estimates and issued 2026 adjusted EPS guidance that tops Street views, driven by strong immunology sales. AbbVie forecasts 2026 profit above estimates
• Positive Sentiment: Skyrizi & Rinvoq are the growth engines — Management said Skyrizi and Rinvoq grew strongly (double‑digit/30%+ rates in 2025), offsetting a smaller‑than‑expected Humira decline and driving the company’s top‑line beat. AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
• Positive Sentiment: Analyst/institutional support — Morgan Stanley nudged up its price target and several analysts/institutions are still accumulating shares, which supports upside case and dividend safety arguments cited by bulls. Analyst price target raise
• Positive Sentiment: Favorable real‑world Rinvoq data — New Japan real‑world data for Rinvoq could expand label/market confidence for ankylosing spondylitis and support future sales momentum. Rinvoq real-world data in Japan
• Neutral Sentiment: Market technical/positioning view — Some commentators describe the post‑earnings pullback as a buying opportunity, citing institutional accumulation and dividend support; this is sentiment/flow driven rather than new fundamental news. MarketBeat dip-is-buy analysis
• Neutral Sentiment: IPR&D / milestone accounting affects comparability — 2025 and some Q4 results include one‑time IPR&D/milestone impacts that complicate GAAP vs. adjusted comparisons; management’s 2026 guidance excludes future IPR&D burdens. PR Newswire results & IPR&D note
• Negative Sentiment: Near‑term guidance and Q1 caution — AbbVie set Q1 2026 EPS guidance below some quarterly consensus and issued a slightly softer near‑term revenue tone (market focused on the lower quarterly guide even as full‑year was raised), which contributed to short‑term selling pressure. Earnings call / transcript
• Negative Sentiment: Diversification worries — Analysts flagged weakness in oncology and aesthetics and questioned growth durability beyond immunology, fueling debate about reliance on M&A and milestones to sustain long‑term growth. Seeking Alpha downgrade on diversification
• Negative Sentiment: Rinvoq expansion/valuation questions — Strategic moves such as the Rinvoq vitiligo push raise questions about incremental costs and valuation expectations, which could pressure sentiment if approval/commercial returns are uncertain. Rinvoq vitiligo valuation questions

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.